Skip to main navigation

Contact Us
Global
- International
- Canada
- France
- Germany
- Italy
- Japan
- Netherlands
- Spain

About Amicus
- About Amicus
- Chairman’s Welcome
- Leadership
- Belief Statement
- Contact Us
- Message from BIO
Patient Advocacy
- Patient Advocacy
- Disease Information
- Rare Stories
- Patient Advisory Boards
- Corporate Giving
- Resources
- Expanded Access
Programs & Pipeline
- Programs & Pipeline
- Our Pipeline
- Fabry Disease
- Pompe Disease
- Batten Disease
- Additional Preclinical Programs
- Clinical Trials
- Platform Technologies
- Journal Articles
- Publications & Posters
Product
- Product
- Galafold^®
- Amicus Assist™
Responsibility
- Responsibility
- Ethics & Compliance
- Global Medical Affairs
- Corporate Giving
- Healing Beyond Disease
- ESG Report
Investors & Media
- Investors & Media
- Investor Relations
- Senior Management Team
- Board of Directors
- Corporate Governance
- Press Releases
- Events & Presentations
- Annual Reports and Proxies
- SEC Filings
- Stock Performance
- Investor FAQs
- Contact Us
- Sign Up for Email Alerts
- Featured Coverage
- Electronic Press Kit
Careers
- Careers
- Overview
- Search

Investors

Press Releases

Press Releases

Year

December 3, 2021

European Medicines Agency Validates Amicus Therapeutics Marketing Authorization Applications for AT-GAA for the Treatment of Pompe Disease

November 24, 2021

Amicus Therapeutics to Present at the 4th Annual Evercore ISI HealthCONx Virtual Conference

November 22, 2021

Amicus Therapeutics Announces Presentations at the 14th International Congress of Inborn Errors of Metabolism

November 18, 2021

The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease

November 11, 2021

Amicus Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

November 9, 2021

Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates

November 3, 2021

Amicus Therapeutics to Announce Third Quarter 2021 Financial Results on November 9, 2021

September 29, 2021

Amicus Therapeutics and ARYA Sciences Acquisition Corp IV Announce Formation of a Next-Generation Genetic Medicine Company: “Caritas Therapeutics”

September 29, 2021

U.S. FDA Accepts Filings for Amicus’ AT-GAA for the Treatment of Pompe Disease

September 20, 2021

Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

About Amicus

Patient Advocacy

Programs & Pipeline

Product
- Overview
- Amicus Assist™

Responsibility

Investors & Media

Careers
- Overview
- Search

Social Media
- Twitter
- YouTube
- LinkedIn

Copyright © 2021 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119

Cookies Statement
Terms of Use
Privacy Notice
Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional